Overdose Risk Management and Naloxone

Overdose Risk Management and Compensation in the Era of Naloxone

A growing body of research underscores the life- and cost-saving advantages of equipping people who use opioids with naloxone, but very little is known about: 1) barriers to naloxone awareness and access, and 2) the potential psychosocial and behavioral impacts of being "protected" by naloxone while engaging in overdose risk behaviors, of using naloxone on someone else, and of surviving an overdose in which naloxone is used. This research will provide insight into both of these domains to yield a richly contextualized understanding of the processes and mechanisms underlying changes in overdose risk behaviors related to naloxone access and use and will illuminate the disparities that may limit access to naloxone for some or result in compensatory behavior following naloxone exposure for others. Findings from this study will provide an empirical basis to strengthen and refine existing overdose prevention efforts and to design tailored interventions to engage opioid users who have recently survived or reversed an overdose.

Study Overview

• Status: Recruiting
• Conditions: Opioid Use
• Intervention / Treatment: Other: Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.

Detailed Description

Drug overdose (OD) deaths in the United States nearly tripled between 1999 and 2014. During 2015 more than 50,000 people died from overdose nationwide, and almost two thirds (63.1%) involved opioids.1 In response, the number of opioid OD prevention programs offering naloxone has ballooned.2 Many states have sought to expand access through provision of the medication to EMT and police first-responders, over-the-counter availability at pharmacies, and emergency legislation providing for lay prescribing, largely within the context of opioid OD prevention programs serving people who use heroin or diverted prescription opioids (henceforth, people who use illicit opioids; PWUIO). As naloxone has become more commonplace, however, OD rates have continued to rise, and critical viewpoints about the failure of OD reversal efforts to deter subsequent high-risk behavior have begun to emerge from police,3 firefighers,4 EMS personnel,5 and news media,6-8 especially following the recent loss of pop-artist, Prince, to an opioid OD only days after being administered naloxone in an Illinois hospital.9 This study is responsive to a recent NIDA and FDA mandate for foundational naloxone research among active users of illicit opioids.10 Specifically, it assesses two main concerns at the heart of current policymaking related to opioid OD and naloxone. 1) Disparities in access to naloxone and obstacles to a willingness to be trained as a naloxone-carrying OD responder: Despite the critically important role PWUIO can play as OD responders,11-15 questions remain about differential awareness of and access to naloxone and OD response training among PWUIO. Even in NYC where city and state departments of health have led concerted and well-funded efforts to saturate the city with naloxone and OD reversal training, considerable limitations in coverage and training uptake still exist.16 Findings from our ongoing study of opioid OD risks among military veterans in NYC indicate that many PWUIO are still naloxone-naïve and, even after learning about its lifesaving utility, still decline no-cost naloxone and OD response training. 2) The poorly understood impacts of possessing naloxone, using naloxone on someone else, or having it used on oneself on PWUIO's subsequent OD rates and risk behaviors: An increasing number of studies seek to track the uses to which naloxone kits are put, but the broader behavioral impacts of exposure to naloxone on actual opioid-related risk behaviors have seen almost no empirical investigation since 2003 when a study of street-recruited PWUIO in San Francisco reported that 35% indicated that they intended to use more heroin than usual after receiving naloxone.17 Building on our current studies of naloxone use and related attitudes among opioid-using military veterans and other drug users we propose to recruit 600 adult-age (18+) people who use illicit opioids (i.e., heroin and/or diverted pharmaceutical opioids) in New York City using Respondent Driven Sampling. At enrollment, participants will complete a detailed survey instrument establishing histories of substance use, naloxone exposure, and other potential barriers to the uptake of naloxone training. Because extant research establishes a clear public health and ethical imperative to provide PWUIO with naloxone, we will also offer all participants training to become naloxone-equipped OD responders at enrollment. We will follow the sample for two years using a mixed-methods approach involving text-message-based exposure tracking, monthly surveys using a state-of-the-art online data collection portal, and a qualitative subsample to ensure that naloxone exposures and changes in OD risk behavior are carefully tracked and contextualized by ethnographic data about the psychosocial and sociocultural mechanisms underlying participant experiences.

Aim A - Describe factors associated with: 1) lifetime history of access to and use of naloxone and 2) uptake of no-cost naloxone and OD response training. We will test the following hypotheses:

HypA1 - Naloxone knowledge and exposure history will vary at enrollment, potentially revealing disparities based on background factors (e.g., SES, ethnicity, age, neighborhood) and individual level factors (e.g., mental health diagnoses, opioid use disorder severity, duration of opioid use) HypA2 - Interest in OD response training and naloxone at baseline will vary by background and individual-level factors.

Aim B - Describe longitudinal relationships between naloxone exposure (access to and use of naloxone) and overdose risk behaviors. We will test the following hypothesis:

HypB1 - Naloxone access and use exposures will have measurable impacts on opioid OD-related risk behaviors over time, potentially varying in degree and direction across subgroups of PWUIO.

Aim C (Qualitative) - Explore barriers to naloxone uptake and any identified secondary impacts (e.g., compensatory risk taking, positive change after a naloxone exposure such as risk reduction or treatment-seeking) in terms of opioid users' own experiences and perceptions.

By employing a longitudinal and mixed-methods design capable of detecting naloxone exposure impacts and also illuminating the various mechanisms that may undergird them in participants' own terms, this project holds serious policy and direct service implications for the refinement of naloxone training programs and OD risk interventions that target PWUIO. This research also holds the potential to identify varying naloxone impacts among PWUIO of different social and behavioral groups-such as people who inject drugs (PWID) vs. prescription opioid misusers, older vs. younger (or shorter- vs. longer-term) PWUIO, and male vs. female users-and can inform future efforts to tailor prevention and education to these distinct subpopulations.

• Study Type: Observational
• Enrollment (Anticipated): 600

Contacts and Locations

• Study Contact: Name: Alexander Bennett, PhD; Phone Number: 19174707000; Email: bennett@ndri.org
• Study Contact Backup: Name: Luther Elliott, PhD; Phone Number: 3473266757; Email: elliott@ndri.org

Study Locations

• United States
  • New York
    • New York, New York, United States, 10010
      • Recruiting
      • National Development and Research Institutes, Inc.
      • Contact: Luther Elliott, PhD; Phone Number: 3473266757; Email: elliott@ndri.org
      • Contact: Alexander S Bennett, PhD; Phone Number: 917-470-7000; Email: bennett@ndri.org
    • New York, New York, United States, 10001
      • Recruiting
      • 270 West 25th Street
      • Contact: Gina Bonilla, BA; Phone Number: 917-736-3288; Email: Bonilla@ndri.org
      • Contact: Bethany Medley, MSW; Phone Number: 804 551 1532; Email: medley@ndri.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Study population will consist of 600 people who use illicit opioids in New York City.

Description

Inclusion criteria:

• Adult-age (18+)
• Current illicit opioid use (verified by rapid urine screen)
• Speak English
• Willing to participate

Exclusion Criteria:

• Unable to comprehend informed consent and/or study procedures.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

People who use illicit opioids; The study will recruit an adult-age (18+) sample of 600 people who use illicit opioids (either heroin or prescription opioid analgesics without a doctor's prescription) in New York City using Respondent Driven Sampling.

Other: Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.; At enrollment, participants will complete a detailed survey instrument establishing histories of substance use, naloxone exposure, and other potential barriers to the uptake of naloxone training. Because extant research establishes a clear public health and ethical imperative to provide PWUIO with naloxone, we will also offer all participants training to become naloxone-equipped OD responders at enrollment. We will follow the sample for two years using a mixed-methods approach involving text-message-based exposure tracking, monthly surveys using a state-of-the-art online data collection portal, and a qualitative subsample to ensure that naloxone exposures and changes in OD risk behavior are carefully tracked and contextualized by ethnographic data about the psychosocial and sociocultural mechanisms underlying participant experiences.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Naloxone access	Number of times offered naloxone	Lifetime (at baseline)
Naloxone uptake	Number of times accepted naloxone when offered	Lifetime (at baseline)
Naloxone use	Number of times used naloxone	Lifetime (at baseline)
Naloxone access	Number of times offered naloxone	24 months
Naloxone use	Number of times used naloxone	24 months
Overdose risk behaviors	Overdose Risk Behavior Scale - a 22 item validated scale that measures past 30-day overdose risk behaviors. See (Development of an Overdose Risk Behavioral Scale: ORBS; Pouget et al., 2017).	24 months

Collaborators and Investigators

• Sponsor: National Development and Research Institutes, Inc.
• Collaborators: New York University; Rhode Island Hospital; Drexel University; Brandeis University
• Investigators: Study Director: Andrew Rosenblum, National Development & Research Institutes (NDRI)

Publications and helpful links

General Publications

• Pouget ER, Bennett AS, Elliott L, Wolfson-Stofko B, Almenana R, Britton PC, Rosenblum A. Development of an opioid-related Overdose Risk Behavior Scale (ORBS). Subst Abus. 2017 Jul-Sep;38(3):239-244. doi: 10.1080/08897077.2017.1282914. Epub 2017 Jan 23.

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 5, 2019
• Primary Completion (ANTICIPATED): August 1, 2022
• Study Completion (ANTICIPATED): August 31, 2023

Study Registration Dates

• First Submitted: April 23, 2019
• First Submitted That Met QC Criteria: April 29, 2019
• First Posted (ACTUAL): May 1, 2019

Study Record Updates

• Last Update Posted (ACTUAL): May 1, 2019
• Last Update Submitted That Met QC Criteria: April 29, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Keywords: Opioids; Naloxone; Overdose; Overdose Risk Behaviors
• Additional Relevant MeSH Terms: Chemically-Induced Disorders; Substance-Related Disorders; Drug Overdose; Physiological Effects of Drugs; Peripheral Nervous System Agents; Sensory System Agents; Narcotic Antagonists; Naloxone
• Other Study ID Numbers: 660

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No